Dual enkephalinase inhibitors and their role in chronic pain management Review


Authors: Southerland, W. A.; Gillis, J.; Kuppalli, S.; Fonseca, A.; Mendelson, A.; Horine, S. V.; Bansal, N.; Gulati, A.
Review Title: Dual enkephalinase inhibitors and their role in chronic pain management
Abstract: Purpose of Review: Dual enkephalinase inhibitors (DENKIs) are pain medications that indirectly activate opioid receptors and can be used as an alternative to traditional opioids. Understanding the physiology of enkephalins and their inhibitors and the pharmacology of these drugs will allow for proper clinical application for chronic pain patients in the future. Recent Findings: DENKIs can be used as an alternative mode of analgesia for patients suffering from chronic pain by preventing the degradation of endogenous opioid ligands. By inhibiting the two major enkephalin-degrading enzymes (neprilysin and aminopeptidase N), DENKIs can provide analgesia with less adverse effects than nonendogenous opioids. Summary: The purpose of this paper is to review the current literature investigating DENKIs and explore their contribution to chronic pain management. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Keywords: chronic pain; analgesia; pain management; endogenous opioid; multimodal analgesia; enkephalinase inhibitors
Journal Title: Current Pain and Headache Reports
Volume: 25
Issue: 5
ISSN: 1531-3433
Publisher: Springer  
Date Published: 2021-05-01
Start Page: 29
Language: English
DOI: 10.1007/s11916-021-00949-0
PUBMED: 33761014
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 3 May 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Amitabh Gulati
    153 Gulati